WD Rutherford LLC Buys 220 Shares of Stryker Co. (NYSE:SYK)

WD Rutherford LLC boosted its position in Stryker Co. (NYSE:SYK) by 2.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,425 shares of the medical technology company’s stock after buying an additional 220 shares during the quarter. WD Rutherford LLC’s holdings in Stryker were worth $2,639,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Wedge Capital Management L L P NC lifted its stake in Stryker by 16.2% in the third quarter. Wedge Capital Management L L P NC now owns 780 shares of the medical technology company’s stock worth $213,000 after purchasing an additional 109 shares during the last quarter. DAVENPORT & Co LLC boosted its holdings in Stryker by 5.1% during the 3rd quarter. DAVENPORT & Co LLC now owns 13,214 shares of the medical technology company’s stock valued at $3,611,000 after acquiring an additional 642 shares during the period. Cedar Brook Financial Partners LLC lifted its position in shares of Stryker by 14.0% in the 3rd quarter. Cedar Brook Financial Partners LLC now owns 958 shares of the medical technology company’s stock worth $262,000 after purchasing an additional 118 shares during the period. Strategic Blueprint LLC boosted its stake in shares of Stryker by 39.8% during the 3rd quarter. Strategic Blueprint LLC now owns 980 shares of the medical technology company’s stock valued at $268,000 after purchasing an additional 279 shares in the last quarter. Finally, Washington Trust Advisors Inc. increased its position in shares of Stryker by 14.0% during the third quarter. Washington Trust Advisors Inc. now owns 416 shares of the medical technology company’s stock valued at $114,000 after buying an additional 51 shares during the period. 77.09% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Canaccord Genuity Group raised Stryker from a “hold” rating to a “buy” rating and lifted their price objective for the company from $315.00 to $360.00 in a research report on Wednesday, January 31st. Wells Fargo & Company increased their price objective on Stryker from $336.00 to $364.00 and gave the stock an “overweight” rating in a report on Wednesday, January 31st. Truist Financial raised their price objective on Stryker from $330.00 to $345.00 and gave the company a “hold” rating in a research report on Wednesday, January 31st. Evercore ISI upped their target price on shares of Stryker from $340.00 to $370.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. Finally, TD Cowen boosted their price objective on shares of Stryker from $365.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, April 11th. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $340.67.

Insider Activity

In related news, Director Allan C. Golston sold 3,273 shares of the firm’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $341.00, for a total value of $1,116,093.00. Following the transaction, the director now directly owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, CAO William E. Berry, Jr. sold 7,690 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now directly owns 3,675 shares in the company, valued at approximately $1,317,414. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Allan C. Golston sold 3,273 shares of Stryker stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the transaction, the director now directly owns 14,242 shares in the company, valued at approximately $4,856,522. The disclosure for this sale can be found here. Insiders sold a total of 212,109 shares of company stock valued at $72,845,768 in the last 90 days. Company insiders own 5.90% of the company’s stock.

Stryker Stock Performance

Shares of SYK opened at $335.61 on Friday. The firm has a market capitalization of $127.69 billion, a P/E ratio of 40.68, a PEG ratio of 2.71 and a beta of 0.89. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.58 and a quick ratio of 0.97. Stryker Co. has a one year low of $249.98 and a one year high of $361.41. The business has a fifty day moving average of $348.88 and a 200 day moving average of $314.88.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.27 by $0.19. The business had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The business’s quarterly revenue was up 11.8% compared to the same quarter last year. During the same period in the previous year, the company posted $3.00 EPS. As a group, sell-side analysts anticipate that Stryker Co. will post 11.86 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be paid a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a dividend yield of 0.95%. The ex-dividend date of this dividend is Wednesday, March 27th. Stryker’s dividend payout ratio is presently 38.79%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.